Patent · US Expired

Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy

US5876950A · kind A · utility

50Cited by
4References
50Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 26, 1995
Grant dateMar 2, 1999
Priority date
Expiry dateJan 26, 2015

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides monoclonal antibodies, antigen binding fragment and recombinant binding proteins specific for human gp39. These antibodies are specific for at least eight different epitopes on gp39. Hybridomas secreting specific antibodies which bind to these epitopes are also provided. Further, the present invention discloses the amino acid sequence of immunoglobulin light and heavy chain variable regions which bind to epitopes of gp39 and provide sFv and humanized antibodies which bind gp39. Also, provided are pharmaceutical compositions comprising the monoclonal antibodies, antigen binding fragments and recombinant binding proteins which bind gp39 and methods for using these compositions in diagnosing disease states, inhibiting B cell activation and for treating immunological disorders, such as autoimmune diseases, allergic responses, organ rejection and graft-versus-host disease. Antibodies of the present invention can also be used to image cells which express gp39 on their surface, such as tumor cells (e.g., lymphoma) and to target therapeutic agents to target cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.